Cargando…
Dasiglucagon Effects on QTc in Healthy Volunteers: A Randomized, Placebo-Controlled, Dose-Escalation, Double-Blind Study
BACKGROUND: Dasiglucagon is a novel glucagon analog that is stable in aqueous formulation and approved for use in severe hypoglycemia. Concentration QTc analyses are critical for assessing risk of drug-induced QTc prolongation and potential for fatal cardiac arrhythmias such as torsades de pointes....
Autores principales: | Tehranchi, Ramin, Pettersson, Jonas, Melgaard, Anita E., Seitz, Friedeborg, Valeur, Anders, Maarbjerg, Stine Just |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026613/ https://www.ncbi.nlm.nih.gov/pubmed/35464292 http://dx.doi.org/10.1016/j.curtheres.2022.100668 |
Ejemplares similares
-
Dasiglucagon, a next‐generation ready‐to‐use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial
por: Battelino, Tadej, et al.
Publicado: (2021) -
Dasiglucagon—A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial
por: Pieber, Thomas R., et al.
Publicado: (2021) -
Absence of QTc Prolongation with Domperidone: A Randomized, Double-Blind, Placebo- and Positive-Controlled Thorough QT/QTc Study in Healthy Volunteers
por: Biewenga, Jeike, et al.
Publicado: (2015) -
Evaluating Ease of Use and Patient Safety of Dasiglucagon Hypo Pal Autoinjector for the Management of Hypoglycemia
por: Schaumleffel, Carol
Publicado: (2023) -
Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model
por: Hinahara, Jordan, et al.
Publicado: (2022)